Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial
Among children (6 to <12 years of age) with obesity, treatment with liraglutide for 56 weeks plus lifestyle interventions resulted in a greater reduction in BMI than placebo plus lifestyle interventions. (Funded by Novo Nordisk; SCALE Kids ClinicalTrials.gov number, NCT04775082.).
Authors
- Muhammad Yazid Jalaludin (ORCID: https://orcid.org/0000-0003-4513-8444)
- Petra Weimers (ORCID: https://orcid.org/0000-0002-7646-3728)
- Silva Arslanian (ORCID: https://orcid.org/0000-0002-1528-9324)
- John M. D’Cruz
- Eric M. Bomberg (ORCID: https://orcid.org/0000-0002-8037-4314)
- Nina M. Harder‐Lauridsen (ORCID: https://orcid.org/0000-0002-8651-5544)
- Inge Gies (ORCID: https://orcid.org/0000-0002-8571-0858)
- Margarita Barrientos‐Pérez (ORCID: https://orcid.org/0000-0002-7089-7576)
- Claudia K. Fox (ORCID: https://orcid.org/0000-0001-5732-0062)
- Thomas Zueger
- Kushal Sahu
Institutions
- University of Bern (CH)
- Novo Nordisk (Denmark) (DK)
- University Hospital of Bern (CH)
- University of Malaya (MY)
- Universitair Ziekenhuis Brussel (BE)
- Children's Hospital of Pittsburgh (US)
- University of Pittsburgh Medical Center (US)
- University of Minnesota Medical Center (US)
- Kantonsschule Olten (CH)
- Novo Nordisk (Germany) (DE)
- Novo Nordisk (India) (IN)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1056/nejmoa2407379
- Citations
- 93
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 33.27
Funders
- Novo Nordisk